Loading…
Makes ready-to-use injectable and delivery technologies for hormone deficiency and endocrine drugs.
Makes ready-to-use injectable and delivery technologies for hormone deficiency and endocrine drugs.
Earns from selling three branded drugs in the US, mostly through wholesalers and pharmacies, with insurers deciding coverage. Gvoke serves diabetes, a large patient group, while Recorlev and Keveyis treat rare conditions with few prescribers. The 2021 merger with Strongbridge Biopharma brought in the two rare-disease drugs.
Moat: narrow (IP / patents, process know-how). Proprietary non-aqueous formulation technology avoids the reconstitution steps needed by rival products.
Headquarters: Chicago, Illinois, US · Founded: 2005 · Employees: 435
Size Xeris Biopharma (XERS) is a United States Health Care company (Biotechnology) with a market value of $2.77B, the 1594th largest of 3,117 United States companies the cockpit tracks. Shares closed at $15.20 on 6 Nov 2026.
Performance Over six months the shares gained 132.8%, against -3.9% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd highest of 20 in its peer set.
Growth Revenue grew 36.3% over the last twelve months (peer median +2.8%); the operating margin is 10.9% (peer median -19.5%).
Valuation It trades at 67.9× forward earnings against a peer median of 36.8× (4th most expensive of 8).
Price implies For today's price to make sense, revenue must grow about 33% a year for seven years (Req g). Recent delivered growth is +70%, so the hurdle is -37 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 9.7 points above its cost of capital (8.6% WACC).
Backlog Backlog (remaining performance obligations) was $6.20M at 30 Sep 2026 — 0.0 years of trailing revenue. Backlog detail →
Short interest Short interest is 4.4% of the free float (15 Oct 2026).
Next results Next results expected around 10 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $335M | $292M | $203M | $164M | $110M |
| Revenue growth | — | +44% | +24% | +49% | — |
| Gross profit | $280M | $238M | $155M | $124M | $76.8M |
| EBITDA | $49.4M | $37.6M | -$21.0M | -$30.9M | -$67.8M |
| Net income | -$17.2M | $554,000 | -$54.8M | -$62.3M | -$94.7M |
| Free cash flow | $55.7M | $27.9M | -$37.8M | -$50.5M | -$103M |
| Capital expenditure | $938,000 | $696,000 | $868,000 | $2.26M | $524,000 |
| Total debt | $289M | $258M | $271M | $229M | $198M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Xeris Biopharma XERS | $2.77B | +133% | +36% | 11% | 67.9× | 33.3% |
| Lilly (Eli) LLY | $1.27T | +43% | +46% | 51% | 28.9× | 5.9% |
| Novo Nordisk A/S NOVO-B.CO | $190B | -7% | +6% | 48% | 11.9× | 0.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | XERS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +49.2% | -6.6% | highest of 21 |
| 6-month return | +132.8% | -3.9% | 2nd highest of 20 |
| Distance from 52-week high | -0.1% | -30.1% | highest of 21 |
| Revenue growth (TTM) | +36.3% | +2.8% | 3rd highest of 17 |
| Operating margin | 10.9% | -19.5% | 5th highest of 17 |
| Forward P/E | 67.9× | 36.8× | 4th most expensive of 8 |
| Growth the price implies (Req g, 7 yrs) | 33.3% | -0.2% | most demanding of 5 |
| Growth delivered (Del g) | +70.2% | +31.7% | highest of 5 |
| Hurdle (Req g minus delivered) | -36.9 pp | -32.5 pp | 2nd least demanding of 5 |
| ROIC minus cost of capital | +9.7 pp | -10.2 pp | 3rd highest of 15 |
| EV / EBITDA | 59.5× | 37.0× | 3rd cheapest of 5 |
| Net debt / EBITDA | 3.4× | 0.3× | 3rd most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Xeris Biopharma XERS | United States | $2.77B | +133% | +36% | 11% | 67.9× | 33.3% | +70.2% |
| Xiamen Amoytop Biotech 688278.SS | China | $2.76B | -23% | +18% | 27% | 16.2× | 0.5% | +36.0% |
| Beam Therapeutics BEAM | United States | $2.73B | -18% | +163% | -268% | n/a | n/a | n/a |
| Walvax Biotechnology 300142.SZ | China | $2.71B | -12% | -23% | 5% | 381.7× | 31.3% | -3.8% |
| ADMA Biologics ADMA | United States | $2.85B | +56% | +8% | 42% | 15.7× | -0.8% | +64.6% |
| Sunshine Lake Pharma 6887.HK | Hong Kong | $2.85B | -9% | +20% | -3% | n/a | n/a | n/a |
| Hebei Changshan Biochemical Pharmaceutical 300255.SZ | China | $2.68B | -52% | 0% | -25% | n/a | n/a | n/a |
| Xencor XNCR | United States | $2.66B | +178% | -29% | -206% | n/a | n/a | n/a |
| Rubicon Research RUBICON.NS | India | $2.91B | +74% | +37% | 21% | 77.2× | n/a | n/a |
| Zai Lab 9688.HK | Hong Kong | $2.92B | +13% | +5% | -59% | n/a | n/a | n/a |
| Bavarian Nordic A/S BAVA.CO | Denmark | $2.93B | +27% | -3% | 16% | 17.1× | -2.0% | +27.4% |
| Arcus Biosciences RCUS | United States | $2.59B | -28% | -55% | -415% | n/a | n/a | n/a |
| Evopoint Biosciences 688837.SS | China | $2.58B | n/a | n/a | n/a | n/a | n/a | n/a |
| Caliway Biopharmaceuticals 6919.TW | Taiwan | $3.01B | -37% | -54% | -6,983% | n/a | n/a | n/a |
| Palvella Therapeutics PVLA | United States | $2.53B | +45% | -100% | n/a | n/a | n/a | n/a |
| HLB 028300.KS | South Korea | $3.06B | -49% | +29% | -96% | n/a | n/a | n/a |
| MBX Biosciences MBX | United States | $2.47B | +25% | n/a | n/a | n/a | n/a | n/a |
| Pharvaris PHVS | United States | $2.41B | +14% | n/a | n/a | n/a | n/a | n/a |
| Denali Therapeutics DNLI | United States | $3.22B | +2% | n/a | -2,488% | n/a | n/a | n/a |
| BGI Genomics 300676.SZ | China | $2.39B | -4% | 0% | -14% | 142.2× | n/a | n/a |
| Telix Pharmaceuticals TLX.AX | Australia | $3.22B | -6% | +27% | -1% | 36.8× | n/a | n/a |
Xeris Biopharma reported $6.20M of remaining performance obligations at 30 Sep 2026 and up 24% from the previous quarter. That is 0.0 years of trailing revenue already under contract. Book-to-bill last quarter: 1.01.